Literature DB >> 18021186

Generation of MUC1-stimulated mononuclear cells using optimized conditions.

S E Wright1, R Khaznadar, Z Wang, I S Quinlin, K A Rewers-Felkins, C A Phillips, S Patel.   

Abstract

Mucin is a glycoprotein found on the surface of cell membranes of adenocarcinomas. The purpose of these studies was to generate MUC1 multiple tandem repeat (VNTR)-stimulated mononuclear cells (M1SMC). We first determined the optimal conditions to influence the immune response. In these studies, peripheral blood mononuclear cells (PBMC), from patients with adenocarcinomas, were stimulated by different numbers of M1SMC stimulations, various concentrations of MUC1 peptide, washing of PBMC prior to stimulation and days in culture, to determine the optimal conditions to influence the immune response. The results of this study indicate that the mononuclear cells (MC) stimulated twice 1 week apart with MUC1 VNTR1 produced a greater specific killing of the breast cancer cell line MCF-7 than the 0, 1, 3 or 4 weekly stimulations. The optimal molarity for inducing cytotoxicity and cytokines (granulocyte macrophage colony-stimulating factor, gamma-interferon and interleukin-10) was 45 x 10(-8) M (1 microg/ml); except for tumour necrosis factor (TNF)-alpha which was 22 x 10(-8) M (0.5 microg/ml). The unwashed MC were superior to washing them with Ficoll-Hypaque. The optimal number of days in culture for cytotoxicity and cytokine production was after two stimulations (i.e. after day 7). Optimum conditions for generation of M1SMC identified in these studies were two stimulations with peptide, concentration of 45 x 10(-8) M (1 microg/ml) peptide, unwashed cells, and after two stimulations or after 8 days in culture. M1SMC were generated from multiple patients with breast cancer which lysed adenocarcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021186     DOI: 10.1111/j.1365-3083.2007.02032.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Catherine A Phillips; Mary Townsend; Ramila Philip; Mark J Dobrzanski; Pamela R Lockwood-Cooke; William Robinson
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda Quinlin; Fatema Zohra; Jewel Ahmed
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

3.  Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Khaliquzzaman A Samad; Imelda S Quinlin; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Cancer Immunol Immunother       Date:  2011-11-15       Impact factor: 6.968

Review 4.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

5.  Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Imelda S Quinlin; Khaliquzzaman A Samad; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Clin Immunol       Date:  2009-09-16       Impact factor: 3.969

6.  Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.

Authors:  Zhenyao Wang; Monte D Hall; Kathleen A Rewers-Felkins; Imelda S Quinlin; Stephen E Wright
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

7.  TGFα-PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda Quinlin; Nazrul I Chowdhury; Jewel Ahmed; Paul W Eldridge; Sanjay K Srivastava; Ira Pastan
Journal:  Oncol Lett       Date:  2014-03-12       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.